Brief: Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study
18/12/2023 12:41
Dec 18 (Reuters) - Cara Therapeutics Inc CARA.O :
* CARA THERAPEUTICS ANNOUNCES OUTCOME FROM DOSE-FINDING PART
A OF
KIND 1 STUDY EVALUATING ORAL DIFELIKEFALIN FOR
MODERATE-TO-SEVERE PRURITUS IN PATIENTS WITH ATOPIC DERMATITIS
* CARA THERAPEUTICS INC - EXPECTS TO END 2023 WITH
APPROXIMATELY
$100 MILLION IN CASH
Source text for Eikon: ID:nGNX39g6dy
Further company coverage: CARA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM